BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,000+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally discovered product in the United States, BRUKINSA® (zanubrutinib).